Armistice Capital LLC Raises Position in Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Armistice Capital LLC increased its holdings in Ironwood Pharmaceuticals by 44.7%, acquiring 4,232,000 additional shares and owning a total of 13,700,000 shares, representing 8.47% of the company.
• Ironwood Pharmaceuticals reported a quarterly earnings per share (EPS) of $0.14, exceeding the consensus estimate and generating revenue of $85.24 million, which also surpassed expectations.
• Wall Street analysts have recently upgraded Ironwood Pharmaceuticals' stock rating from "hold" to "strong-buy", with a consensus target price of $4.94.

Armistice Capital LLC lifted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 44.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,700,000 shares of the biotechnology company's stock after buying an additional 4,232,000 shares during the quarter. Armistice Capital LLC owned approximately 8.47% of Ironwood Pharmaceuticals worth $20,139,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Deutsche Bank AG increased its holdings in Ironwood Pharmaceuticals by 47.4% during the 4th quarter. Deutsche Bank AG now owns 1,567,535 shares of the biotechnology company's stock worth $6,944,000 after purchasing an additional 504,336 shares during the period. GSA Capital Partners LLP increased its stake in shares of Ironwood Pharmaceuticals by 3,683.6% during the first quarter. GSA Capital Partners LLP now owns 524,676 shares of the biotechnology company's stock worth $771,000 after buying an additional 510,809 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Ironwood Pharmaceuticals by 1,130.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,521 shares of the biotechnology company's stock worth $78,000 after buying an additional 16,097 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $1,888,000. Finally, Cerity Partners LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $142,000.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of "Hold" and an average price target of $4.94.

Ironwood Pharmaceuticals Stock Performance

Ironwood Pharmaceuticals stock traded up $0.05 during midday trading on Friday, reaching $1.15. 598,693 shares of the company were exchanged, compared to its average volume of 2,760,516. The company has a market capitalization of $185.98 million, a price-to-earnings ratio of -22.88 and a beta of 0.33. The firm's 50-day simple moving average is $0.93 and its 200-day simple moving average is $1.00. Ironwood Pharmaceuticals, Inc. has a 1 year low of $0.53 and a 1 year high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.16. The firm had revenue of $85.24 million during the quarter, compared to analyst estimates of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.